CRISPR Therapeutics AG Quarterly Cash and Cash Equivalents, at Carrying Value in USD from Q4 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Summary
CRISPR Therapeutics AG quarterly Cash and Cash Equivalents, at Carrying Value history and growth rate from Q4 2013 to Q3 2024.
  • CRISPR Therapeutics AG Cash and Cash Equivalents, at Carrying Value for the quarter ending September 30, 2024 was $226M, a 57.2% decline year-over-year.
Cash and Cash Equivalents, at Carrying Value, Quarterly (USD)
Cash and Cash Equivalents, at Carrying Value, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $226M -$302M -57.2% Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $484M +$39.7M +8.92% Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $707M +$363M +105% Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $389M +$178M +83.8% Dec 31, 2023 10-Q 2024-11-05
Q3 2023 $528M +$33.6M +6.8% Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $445M -$52.1M -10.5% Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $344M -$339M -49.6% Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $212M -$711M -77% Dec 31, 2022 10-K 2024-02-21
Q3 2022 $494M -$517M -51.1% Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $497M -$1.15B -69.8% Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $684M -$442M -39.3% Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $923M -$246M -21% Dec 31, 2021 10-K 2024-02-21
Q3 2021 $1.01B -$29.9M -2.87% Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $1.65B +$702M +74.2% Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $1.13B +$236M +26.6% Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $1.17B +$225M +23.8% Dec 31, 2020 10-K 2023-02-21
Q3 2020 $1.04B +$412M +65.4% Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $945M +$517M +121% Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $890M +$452M +103% Mar 31, 2020 10-Q 2021-04-27
Q4 2019 $944M +$487M +107% Dec 31, 2019 10-K 2022-02-15
Q3 2019 $630M +$142M +29.2% Sep 30, 2019 10-Q 2020-10-28
Q2 2019 $428M +$108M +33.8% Jun 30, 2019 10-Q 2020-07-27
Q1 2019 $438M +$95.8M +28% Mar 31, 2019 10-Q 2020-04-28
Q4 2018 $457M +$217M +90.5% Dec 31, 2018 10-K 2021-02-16
Q3 2018 $487M +$234M +92.2% Sep 30, 2018 10-Q 2019-10-28
Q2 2018 $320M +$47.5M +17.4% Jun 30, 2018 10-Q 2019-07-29
Q1 2018 $342M +$52.9M +18.3% Mar 31, 2018 10-Q 2019-04-29
Q4 2017 $240M -$75.8M -24% Dec 31, 2017 10-K 2020-02-12
Q3 2017 $254M +$24.9M +10.9% Sep 30, 2017 10-Q 2017-11-08
Q2 2017 $272M +$25.4M +10.3% Jun 30, 2017 10-Q 2017-08-10
Q1 2017 $289M +$88.3M +44% Mar 31, 2017 10-Q 2017-05-11
Q4 2016 $316M +$160M +102% Dec 31, 2016 10-K 2019-02-25
Q3 2016 $229M +$180M +366% Sep 30, 2016 10-Q 2017-11-08
Q2 2016 $247M Jun 30, 2016 10-Q 2017-08-10
Q1 2016 $201M Mar 31, 2016 10-Q 2017-05-11
Q4 2015 $156M +$155M +16404% Dec 31, 2015 10-K 2018-03-08
Q3 2015 $49M Sep 30, 2015 10-Q 2016-11-22
Q4 2014 $945K -$360M -99.7% Dec 31, 2014 10-K 2018-03-08
Q4 2013 $361M Dec 31, 2013 10-K 2017-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.